IPSEN (OTCMKTS:IPSEY) Sees Unusually-High Trading Volume – Time to Buy?

IPSEN (OTCMKTS:IPSEY) saw strong trading volume on Tuesday. 3,850 shares were traded during mid-day trading, an increase of 95% from the average daily volume of 1,975 shares. The stock last traded at $42.35 and had previously closed at $43.56.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Barclays raised IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Finally, Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold”.

IPSEN Stock Performance

The business’s 50-day moving average is $44.24 and its two-hundred day moving average is $45.06.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.